Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 3/20 | 0.61 |
| ▸ | CA1 | P00915 | 2/20 | 0.61 |
| ▸ | CA2 | P00918 | 2/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.55 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.55 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.50 |
| ▸ | TUBB | P07437 | 1/20 | 0.50 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.50 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.50 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.50 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.50 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.50 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.50 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.50 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.50 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.50 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.50 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.50 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.50 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29952001 | 1.00 | ENPP2 (0.61) | ENPP2CA1CA2CYP1A2CYP2A6 | |
| SCHEMBL29410294 | 0.96 | ENPP2 (0.65) | ENPP2CA1CA2CYP1A2CYP2A6 | |
| SCHEMBL9210 | 0.96 | ENPP2 (0.65) | ENPP2CA1CA2CYP1A2CYP2A6 | |
| SCHEMBL12420001 | 0.81 | ENPP2 (0.62) | ENPP2CA1CA2CYP1A2CYP2A6 | |
| SCHEMBL443528 | 0.81 | CYP2A6 (0.80) | CA1CA2CYP1A2CYP2A6RAB9A | |
| SCHEMBL29367032 | 0.81 | CYP2A6 (0.80) | CA1CA2CYP1A2CYP2A6RAB9A | |
| SCHEMBL28784898 | 0.81 | CA2 (0.76) | ENPP2CA1CA2KDM4ETSHR | |
| SCHEMBL19451064 | 0.81 | CYP1A2 (0.50) | ENPP2CA1CA2CYP1A2CYP2A6 | |
| SCHEMBL13667343 | 0.79 | CA2 (0.73) | ENPP2CA1CA2KDM4ETSHR | |
| SCHEMBL31354846 | 0.78 | CA2 (0.80) | ENPP2CA1CA2KDM4ETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8252790-B2 | Pyrazole-3-carboxamide derivative having 5-HT2B receptor antagonist activity | RAQUALIA PHARMA INC. (JP) | 2012-08-28 | — | — | US | disclosed |
| US-8252790-B2 | Pyrazole-3-carboxamide derivative having 5-HT2B receptor antagonist activity | RAQUALIA PHARMA INC. (JP) | 2012-08-28 | — | — | US | disclosed |
| EP-2386546-A1 | NOVEL PYRAZOLE-3-CARBOXAMIDE DERIVATE HAVING 5-HT2B RECEPTOR ANTAGONIST ACTIVITY | RaQualia Pharma Inc (JP) | 2011-11-16 | — | — | EP | disclosed |
| US-20110275628-A1 | NOVEL PYRAZOLE-3-CARBOXAMIDE DERIVATIVE HAVING 5-HT2B RECEPTOR ANTAGONIST ACTIVITY | RAQUALIA PHARMA INC. (JP) | 2011-11-10 | — | — | US | disclosed |
| US-20110275628-A1 | NOVEL PYRAZOLE-3-CARBOXAMIDE DERIVATIVE HAVING 5-HT2B RECEPTOR ANTAGONIST ACTIVITY | RAQUALIA PHARMA INC. (JP) | 2011-11-10 | — | — | US | disclosed |
| WO-2010058858-A1 | NOVEL PYRAZOLE-3-CARBOXAMIDE DERIVATIVE HAVING 5-HT2B RECEPTOR ANTAGONIST ACTIVITY | ラクオリア創薬株式会社 (JP) | 2010-05-27 | — | — | WO | disclosed |
| EP-2065383-A1 | Indazole compounds and methods of use thereof as protein kinase inhibitors | Signal Pharmaceuticals, Inc. (US) | 2009-06-03 | — | — | EP | disclosed |
| US-20090099178-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF | BHAGWAT SHRIPAD S | 2009-04-16 | — | — | US | disclosed |
| EP-1692128-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF AS PROTEIN KINASE INHIBITORS | Signal Pharmaceuticals LLC (US) | 2006-08-23 | — | — | EP | disclosed |
| US-20060004043-A1 | Indazole compounds and methods of use thereof | BHAGWAT SHRIPAD S | 2006-01-05 | — | — | US | disclosed |
| WO-2005051942-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF AS PROTEIN KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275628-A1 | NOVEL PYRAZOLE-3-CARBOXAMIDE DERIVATIVE HAVING 5-HT2B RECEPTOR ANTAGONIST ACTIVITY | HTR2B, HTR1B, HTR3B | ENPP2 785/4885CA1 3982/4885CA2 1997/4885 |
| US-20090099178-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF | WNT3, WNT3A, WNK3 | ENPP2 1150/4885CA1 3293/4885CA2 1269/4885 |
| US-20060004043-A1 | Indazole compounds and methods of use thereof | WNT3, WNT3A, WNK3 | ENPP2 1206/4885CA1 3295/4885CA2 1341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.